ClinicalTrials.gg
CompletedNCT02397057Updated Oct 12, 2021Results posted

Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS

A Phase 3 interventional study of Injectafer and Placebo in Restless Legs Syndrome (RLS), sponsored by American Regent, Inc.. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-12.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
209
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.

Enrollment
20th of 95
209 · median 46
Started
2015
with 2 others
Phase 3
18 of 107
none open now
Registered
63rd of 107
by date
Lead sponsor
3 of 107
American Regent, Inc.

Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 20th largest by enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2015, is one of 18 in phase 3, and was the 63rd registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Restless Legs Syndrome with a site in United States, or all of them as a file.
02

Study summary

This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 12 months. The subject's participation in the study will be for approximately 1 year from Day 0.

Read the detailed description

This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 12 months. Subjects will visit the clinic on Days 0 and 5 for treatment, and then on Days 14, 42, 168, and 365. In between the clinic visits subjects will be contacted remotely on Days 84, 126, 210, 252, 294, and 336. The subject's participation in the study will be for approximately 1 year from Day 0.

03

Conditions studied

  • Restless Legs Syndrome (RLS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject's ≥18 years of age, willing and able to give to the study.
  2. RLS symptoms affirming diagnosis. The IRLS Diagnostic Criteria must be met:

    1. An urge (distressing need) to move the legs usually associated with painful or uncomfortable sensations in the legs. The urge to move may be present without the uncomfortable sensations. The arms or other body parts may be involved in addition to the legs.
    2. The urge to move or unpleasant sensations are worse or exclusively present at rest or inactivity, such as lying down or sitting.
    3. The urge to move or unpleasant sensations are partially/temporarily relieved with walking or moving the legs.
    4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. When symptoms are severe, the worsening at night may not be noticeable but must have been previously present.
  3. Subjects should be on monotherapy for RLS. Treatment should be stable for at least 8 weeks prior to screening (See approved RLS Therapies/Regimen in Appendix III).
  4. A score ≥15 on the IRLS Rating Scale at screening and on Day 0 prior to dosing.
  5. Subjects on anti-depressants and sleep medications must be on a stable dose for at least 6 months.
  6. Subject has regular sleep hours between 9 pm and 9 am.
  7. Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of : have had a hysterectomy or tubal ligation, or otherwise be incapable of pregnancy, or have practiced any of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide with barrier, intrauterine device, or partner sterility.

Exclusion criteria

Exclusion Criteria:

  1. RLS 2° to other disease or injury.
  2. Disorders that require treatment with the same medications used for RLS include: peripheral neuropathy and neurodegenerative disorders (i.e. Parkinson's Disease or Dementia).
  3. Stage 4 - 5 CKD, subjects on dialysis or anticipated to start dialysis while participating in this study.
  4. Any pain related (e.g., frequent muscle cramps, myalgia, fibromyalgia) or sleep related disorders (e.g. sleep apnea, unless on stable Continuous Positive Airway Pressure [CPAP]) which may confound the outcome measures.
  5. Subjects with multiple sclerosis.
  6. History of neuroleptic akathisia.
  7. Parenteral iron use within 6 weeks prior to screening.
  8. History of >10 blood transfusions in the past 2 years.
  9. Anticipated need for blood transfusion during the study.
  10. Known reaction to any component of Injectafer® (Ferric Carboxymaltose).
  11. Previously randomized to Injectafer® (FCM or VIT-45) in a clinical trial.
  12. Current, active or acute or chronic infection other than viral upper respiratory tract infection
  13. (other than basal or squamous cell skin cancer or the subject has been cancer free for ≥ 5 years).
  14. Pregnant or lactating women.
  15. Seizure disorder currently being treated with medication.
  16. Baseline ferritin ≥300 ng/mL.
  17. Baseline TSAT ≥45%.
  18. History of hemochromatosis, hemosiderosis, or other iron storage disorders.
  19. or ALT greater than 2 times the (ULN).
  20. greater than the ULN.
  21. Known positive antigen (HBsAg), unless positive test can be attributed to receipt of hepatitis B vaccination in childhood or viral antibody (HCV) with evidence of active hepatitis (i.e., AST/ALT greater than the upper limit of normal).
  22. Known positive -1/HIV-2 antibodies (anti-HIV).
  23. Received an drug within 30 days before randomization.
  24. Chronic alcohol or drug abuse within the past 6 months.
  25. Any other pre-existing laboratory abnormality, medical condition or disease, which per the investigator may put the subject at risk if they participate in the study.
  26. Subject unable or unwilling to comply with the study requirements.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
209 participants (actual)

Study arms

  • Active comparator
    Injectafer

    Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.

    Drug: Injectafer

  • Placebo comparator
    Normal Saline

    IV Placebo (15ml of Normal Saline) IV push at 2ml/minute

    Other: Placebo

Interventions

  • Also known as: Ferinject®, Iroprem®, Renegy®

  • OtherPlacebo

    Also known as: Normal Saline

06

What researchers measure

Primary outcomes

  1. International Restless Legs Syndrome (IRLS) Total Score Change From Baseline on Day 42

    Summary of the actual values of IRLS total score on baseline and Day 42, and the change from baseline to Day 42. Eligible subjects were to have met the following requirements prior to receiving additional treatment: A baseline score ≥ 15 on the International Restless Legs Syndrome (IRLS) Rating Scale. The minimum score is 15 with the maximum of 40. A score of less than 15 is not an indicator of RLS. However, a score of 15 or greater is an indicator of RLS. Further increase indicates more severe disease.

    Time frame: Baseline and Day 42

  2. Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I)

    Responder is defined as subjects rated as much or very much improved with the CGI-I on Day 42. Summary of the number (percentage) of CGI-I responder. Per the protocol, the he CGI is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC) and therapeutic response. The scale requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.

    Time frame: Day 42

Secondary outcomes

  1. Clinical Global Impression-Improvement (CGI-S) by Subject

    Similar to the CGI-I except this is self-reported, 7-item scale for assessment of symptoms after treatment with the rating as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

    Time frame: Day 42

  2. Restless Legs Syndrome Quality of Life (RLS-QLI) Change From Baseline to Day 42.

    The Restless Legs Syndrome Quality of Life (RLS-QLI) instrument, a self-assessment, 17-item questionnaire with four scales identified through factor analysis: Daily Function, Social Function, Sleep Quality, and Emotional Well-Being, developed to facilitate clinical research on RLS. Scoring Instructions below: 1. Social Function = Sum (Items 1, 2, 3, 4), subtract 4, divide by 16, multiply by 100 2. Daily Function = Sum (Items 5, 6, 13,14, 15, 16), subtract 6, divide by 24, multiply by 100 3. Sleep Quality = Sum (Item 7, 8, 9, 17), subtract 4, divide by 18, multiply by 100 4. Emotional Well-being = Sum (Items 10, 11, 12), subtract 3, divide by 12, multiply by 100 Note: Resulting scores range between 0-100. Higher scores on the RLS-QLI indicate a lower quality of life. Lower scores indicate a higher quality of life.

    Time frame: Baseline and Day 42

  3. Fatigue Linear Analog Scale Change From Baseline

    The Fatigue Linear Analog Scale is a self-assessment scale in which a 100 mm line is used to measure the severity of fatigue and its effect on a person's activities and lifestyle. The scale severity measure ranges from No Fatigue to Worst Possible Fatigue.

    Time frame: Baseline and Day 42

  4. Medical Outcomes Study(MOS) Sleep Scale Change From Baseline to Day 42

    The MOS-Sleep scale, is a 12-item standardized, validated questionnaire for assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache which has been demonstrated to be sensitive to RLS treatment effects. This questionnaire provides information about sleep quality. Individual questions can be used for analysis but summary or index scores of a group of questions, is more commonly used in analysis. The "quantity of sleep" dimension is the average number of hours of sleep per night reported by the patient and the "optimal sleep" is a dichotomized version that is "yes" when the number of hours of sleep is 7 or 8. The scores of the dimensions and of the sleep problem index were converted to a 0 to 100 scale, with higher scores reflecting more of the attribute implied by the name (e.g. greater sleep disturbance, greater adequacy of sleep).

    Time frame: Change from Baseline and Day 42.

  5. Time Off Pre-Enrollment Prescribed Restless Legs Syndrome (RLS) Medications

    Subjects could start tapering off pre-enrollment prescribed RLS medications after Day 5 until Day 365.

    Time frame: Time from Day 5 to Day 365

07

Results

Posted Oct 12, 2021

Participant flow

Participant flow — Overall Study
MilestoneInjectaferNormal Saline
Started105104
Completed9491
Not completed1113
Withdrew: Withdrawal by subject67
Withdrew: Lost to follow-up43
Withdrew: Death10
Withdrew: Adverse event01
Withdrew: Physician decision01
Withdrew: Subject did not receive study drug01

Outcome measures

PrimaryInternational Restless Legs Syndrome (IRLS) Total Score Change From Baseline on Day 42

Summary of the actual values of IRLS total score on baseline and Day 42, and the change from baseline to Day 42. Eligible subjects were to have met the following requirements prior to receiving additional treatment: A baseline score ≥ 15 on the International Restless Legs Syndrome (IRLS) Rating Scale. The minimum score is 15 with the maximum of 40. A score of less than 15 is not an indicator of RLS. However, a score of 15 or greater is an indicator of RLS. Further increase indicates more severe disease.

Time frame:
Baseline and Day 42
Reported as:
Mean · score on a scale
International Restless Legs Syndrome (IRLS) Total Score Change From Baseline on Day 42
score on a scaleInjectaferNormal Saline
Baseline24.1 ± 6.2724.5 ± 6.05
Day 4215.6 ± 8.6918.7 ± 8.94
Change from Baseline to Day 42-8.7 ± 8.44-5.9 ± 9.07
PrimaryProportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I)

Responder is defined as subjects rated as much or very much improved with the CGI-I on Day 42. Summary of the number (percentage) of CGI-I responder. Per the protocol, the he CGI is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC) and therapeutic response. The scale requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.

Time frame:
Day 42
Reported as:
Count of participants · Participants
Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I)
ParticipantsInjectaferNormal Saline
Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I)3825
Statistical analysis
  • Injectafer vs Normal Saline · Regression, Logistic · p = 0.3690 (p-value was estimated by logistic regression with treatment, region (US, EUR), and baseline RLS medication-related augmentation as fixed factors, and baseline IRLS as a covariate.) · Odds ratio (or): 1.35 · 95% CI 0.70 to 2.63
SecondaryClinical Global Impression-Improvement (CGI-S) by Subject

Similar to the CGI-I except this is self-reported, 7-item scale for assessment of symptoms after treatment with the rating as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

Time frame:
Day 42
Reported as:
Count of participants · Participants
Clinical Global Impression-Improvement (CGI-S) by Subject
ParticipantsInjectaferNormal Saline
Very much improved107
Much improved3019
Minimal change3116
No Change1012
Minimally worse211
Much worse34
Very much worse11
SecondaryRestless Legs Syndrome Quality of Life (RLS-QLI) Change From Baseline to Day 42.

The Restless Legs Syndrome Quality of Life (RLS-QLI) instrument, a self-assessment, 17-item questionnaire with four scales identified through factor analysis: Daily Function, Social Function, Sleep Quality, and Emotional Well-Being, developed to facilitate clinical research on RLS. Scoring Instructions below: 1. Social Function = Sum (Items 1, 2, 3, 4), subtract 4, divide by 16, multiply by 100 2. Daily Function = Sum (Items 5, 6, 13,14, 15, 16), subtract 6, divide by 24, multiply by 100 3. Sleep Quality = Sum (Item 7, 8, 9, 17), subtract 4, divide by 18, multiply by 100 4. Emotional Well-being = Sum (Items 10, 11, 12), subtract 3, divide by 12, multiply by 100 Note: Resulting scores range between 0-100. Higher scores on the RLS-QLI indicate a lower quality of life. Lower scores indicate a higher quality of life.

Time frame:
Baseline and Day 42
Reported as:
Mean · units on a scale
Restless Legs Syndrome Quality of Life (RLS-QLI) Change From Baseline to Day 42.
units on a scaleInjectaferNormal Saline
Baseline55.6 ± 15.054.3 ± 13.08
Day 4265.2 ± 15.4962.8 ± 14.90
Change from Baseline to Day 429.0 ± 12.488.7 ± 14.61
SecondaryFatigue Linear Analog Scale Change From Baseline

The Fatigue Linear Analog Scale is a self-assessment scale in which a 100 mm line is used to measure the severity of fatigue and its effect on a person's activities and lifestyle. The scale severity measure ranges from No Fatigue to Worst Possible Fatigue.

Time frame:
Baseline and Day 42
Reported as:
Mean · units on a scale
Fatigue Linear Analog Scale Change From Baseline
units on a scaleInjectaferNormal Saline
Baseline49.78 ± 26.3257.34 ± 23.61
Day 4238.90 ± 26.2542.57 ± 27.13
Change from Baseline to Day 42-9.98 ± 27.55-16.50 ± 28.32
SecondaryMedical Outcomes Study(MOS) Sleep Scale Change From Baseline to Day 42

The MOS-Sleep scale, is a 12-item standardized, validated questionnaire for assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache which has been demonstrated to be sensitive to RLS treatment effects. This questionnaire provides information about sleep quality. Individual questions can be used for analysis but summary or index scores of a group of questions, is more commonly used in analysis. The "quantity of sleep" dimension is the average number of hours of sleep per night reported by the patient and the "optimal sleep" is a dichotomized version that is "yes" when the number of hours of sleep is 7 or 8. The scores of the dimensions and of the sleep problem index were converted to a 0 to 100 scale, with higher scores reflecting more of the attribute implied by the name (e.g. greater sleep disturbance, greater adequacy of sleep).

Time frame:
Change from Baseline and Day 42.
Reported as:
Least squares mean · score on a scale
Medical Outcomes Study(MOS) Sleep Scale Change From Baseline to Day 42
score on a scaleInjectaferNormal Saline
Medical Outcomes Study(MOS) Sleep Scale Change From Baseline to Day 42-13.086 ± 1.829-9.015 ± 1.902
Statistical analysis
  • Injectafer vs Normal Saline · ANCOVA · p = 0.1108 · Least square(ls) mean difference: -4.071 · 95% CI -9.083 to 0.941
SecondaryTime Off Pre-Enrollment Prescribed Restless Legs Syndrome (RLS) Medications

Subjects could start tapering off pre-enrollment prescribed RLS medications after Day 5 until Day 365.

Time frame:
Time from Day 5 to Day 365
Reported as:
Mean · days
Time Off Pre-Enrollment Prescribed Restless Legs Syndrome (RLS) Medications
daysInjectaferNormal Saline
Time Off Pre-Enrollment Prescribed Restless Legs Syndrome (RLS) Medications34 (34 to 164)61 (61 to 183)
Statistical analysis
  • Injectafer vs Normal Saline · Chi-squared, Corrected · p = 0.0002 (p-value was estimated using continuity-corrected chi-square test.)

Adverse events

Collected over 2 years, I month. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Injectafer1/107 (0.9%)6/107 (5.6%)72/107 (67.3%)
Normal Saline0/101 (0%)4/101 (4%)19/101 (18.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventInjectaferNormal Saline
Haemorrhagic strokeNervous system disorders0/1071/101
CellulitisInfections and infestations0/1071/101
Forearm fractureInjury, poisoning and procedural complications0/1071/101
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1071/101
Diabetes mellitus inadequate controlMetabolism and nutrition disorders1/1070/101
GoutMetabolism and nutrition disorders1/1070/101
HypophosphataemiaMetabolism and nutrition disorders1/1070/101
Cerebral haemorrhageNervous system disorders1/1070/101
SyncopeNervous system disorders1/1070/101
DiarrhoeaGastrointestinal disorders1/1070/101
Most frequent other events
Showing 10 of 15
Most frequent other events
EventInjectaferNormal Saline
NauseaGastrointestinal disorders10/1071/101
HypophosphataemiaMetabolism and nutrition disorders8/1071/101
DizzinessNervous system disorders8/1071/101
HeadacheNervous system disorders5/1076/101
Feeling hotGeneral disorders6/1070/101
FlushingVascular disorders6/1070/101
Blood pressure increasedInvestigations5/1071/101
Alanine aminotransferase increasedInvestigations5/1071/101
Blood pressure systolic increasedInvestigations5/1071/101
Hot flushVascular disorders5/1071/101

Baseline characteristics

One subject did not receive study drug and was excluded from the Safety and Full Analysis Set Populations.

Age, Continuous
Age, Continuous(Years)InjectaferNormal SalineTotal
Mean58.3 ± 12.3156.9 ± 13.7357.6 ± 13.01
Sex: Female, Male
Sex: Female, Male(Participants)InjectaferNormal SalineTotal
Female6971140
Male363268
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)InjectaferNormal SalineTotal
Hispanic or Latino12921
Not Hispanic or Latino9394187
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)InjectaferNormal SalineTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander101
Black or African American246
White10199200
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)InjectaferNormal SalineTotal
United States423476
Europe6567132
Height
Height(cm)InjectaferNormal SalineTotal
Mean167.6 ± 9.4167 ± 9.4167.3 ± 9.4
Weight
Weight(kg)InjectaferNormal SalineTotal
Mean82.8 ± 21.479.1 ± 20.881 ± 21.1
Iron intolerance
Iron intolerance(Participants)InjectaferNormal SalineTotal
No104103207
Yes101

1 further baseline measures are reported on the registry.

08

Study locations

19 sites
  • Coastal Clinical Research, Inc.
    Mobile, Alabama 36608, United States
  • Synergy San Diego
    National City, California 91950, United States
  • Desert Valley Research
    Rancho Mirage, California 92270, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • Neurology Offices of South FL
    Boca Raton, Florida 33428, United States
  • Elite Research Institute
    Miami, Florida 33169, United States
  • MidAmmerica Neuroscience Institute
    Lenexa, Kansas 66214-1505, United States
  • Central Kentucky Research Assoc., Inc.
    Lexington, Kentucky 40509, United States
  • Neuromedical Clinical of Central Louisiana
    Alexandria, Louisiana 71301, United States
  • Ctr for Brain & Neuro Care, LLC
    Fulton, Maryland 20759, United States
  • Massachusetts General Hospital, Sleep Disorders Clinical Research Program
    Boston, Massachusetts 02114, United States
  • Desert Neurology
    Las Vegas, Nevada 89119, United States
  • Neurology Center of Las Vegas
    Las Vegas, Nevada 89128, United States
  • Guilford Neurologic Associates
    Greensboro, North Carolina 27405, United States
  • Metrolina Neurological Associates
    Indian Land, South Carolina 29707, United States
  • Saad Upstate Neurology
    Spartanburg, South Carolina 29307, United States
  • Tri-State Mountain Neurology Associates
    Johnson City, Tennessee 37604, United States
  • Egret Bay Neurology
    Houston, Texas 77058, United States
  • The Polyclinic, Madison Center
    Seattle, Washington 98104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in Jan 2018, 36 months.

Results were first posted in Oct 2021, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2015
First posted
Mar 24, 2015
StartActual
Jan 2015
Primary completionActual
Jan 2018
CompletionActual
Jan 2018
Results first posted
Oct 12, 2021
Last update
Oct 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02397057
Responsible party
Sponsor
First posted
Mar 24, 2015
Start date
Jan 2015
Primary completion
Jan 2018
Completion
Jan 2018
Results posted
Oct 12, 2021
Last update
Oct 12, 2021

Study contacts

Mark Falone, MD
study director · American Regent, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion